BMRN רווח צפוי BioMarin Pharmaceutical Inc.

סמל מסחרי של BioMarin Pharmaceutical (BMRN)

The primary growth of BioMarin Pharmaceutical (BMRN) is based on global sales of the drug Voxzogo, as well as the development of its rare disease portfolio and cost optimization. The corporation is modernizing its laboratories for energy efficiency and strictly filtering industrial emissions. Current profit stands at 1.25. The company's price chart reflects the dynamics of a biopharmaceutical leader investing in molecular biology and gene therapy to combat genetic pathologies.

BMRN: תחזית רווחי החברה biomarin.com 04.07.2022 - 17.11.2026

פילוחי מדדים ואנליטיקה של חברת BioMarin Pharma (BMRN)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח כללי של החברה:BioMarin
מוצרים מוגמרים של BioMarin Pharmaceutical Inc.

To minimize fundamental risks, investors utilize aggregated analyst net income expectations to filter out market noise and determine an asset's fair value. In the case of BioMarin Pharmaceutical (BMRN), the business's projected earnings reflect the monetization of exclusive rights to high-cost therapies for rare pathologies, where high margins and insurance coverage make the dynamics of this indicator the determining factor for long-term share price growth.